Impact of body mass index on clinical outcomes in triple-negative XXXX .

@entity1 @entity0 @entity28 @entity5 @entity1349
BACKGROUND: Obesity is associated with poorer outcomes in @entity1 with hormone receptor-positive @entity0 . This association is not well established for @entity1 with @entity0 ( @entity0 ). In this study, the prognostic effects of body mass index on clinical outcome were evaluated in @entity1 with @entity0 . METHODS: A retrospective study was conducted on 418 @entity1 who were treated between July 1996 and July 2010 for @entity0 . @entity1349 ( @entity1349 ) and @entity1349 ( @entity1349 ) were evaluated in relation to body mass index (BMI) after controlling for clinically significant variables. RESULTS: One hundred twenty-four @entity1 (29.7%) were normal/underweight (BMI  <=24.9 kg/m(2) ), 130 @entity1 (31.1%) were overweight (BMI from 25 to 29.9 kg/m(2) ), and 164 @entity1 (39.2%) were @entity28 (BMI >= 30 kg/m(2) ). At a median follow-up of 37.2 months, there were 105 recurrences (25.1%) and 87 deaths (20.8%). Compared with normal/underweight @entity1 , the multivariate hazard ratio (HR) for @entity1349 was 0.81 (95% confidence interval [CI], 0.49-1.34) for @entity28 @entity1 . Similarly, @entity1349 was not associated with BMI category; @entity28 @entity1 had an HR of death of 0.94 (95% CI, 0.54-1.64) compared with normal/underweight @entity1 . A Cox regression analysis identified the receipt of chemotherapy (HR, 0.25; 95% CI, 0.12-0.52), ductal histology (HR, 0.49; 95% CI, 0.25-0.97), @entity5 (HR, 3.5; 95% CI, 1.35-9.06), and increasing @entity5 size (HR, 1.19; 95% CI, 1.09-1.3) as independent prognostic factors for @entity1349 . CONCLUSIONS: No significant relation between @entity28 and @entity1349 or @entity1349 emerged in @entity1 with @entity0 after controlling for clinically significant factors.
